Review Article
Combination Drug Delivery Approaches in Metastatic Breast Cancer
Table 6
Combination drug delivery systems based on water-soluble polymer conjugates.
| | Carrier composition | Therapeutics | Indication | Status | Targeting | References |
| | HPMA copolymer | Aminoglutethimide + Doxorubicin | Breast cancer | In vitro | Passive | [63, 94] | | HPMA copolymer | Gemcitabine + Doxorubicin | Prostate cancer | In vivo | Passive | [95] | | HPMA copolymer | Doxorubicin + Dexamethasone | General cancer | In vivo | Passive | [96] | | HPMA copolymer | TNP-470 + Alendronate | Bone metastasis | In vivo | Active; bone | [97] | | HPMA copolymer | Paclitaxel + Alendronate | Bone metastasis | In vivo | Active; bone | [98] | | Branched PEG | Epirubicin + Nitric oxide | | In vivo | Passive | [99–101] | | Branched PEG | Camptothecin + BH3 domain peptide | | Iv vivo | Active; LHRH | [102] | | HPMA copolymer | Trastuzumab + PKI166 | HER2 overexpressed breast cancer | In vitro | Active; HER2 | [103] |
|
|
HER2: human epidermal growth factor receptor type 2; HPMA: N-(2-hydroxypropyl)methacrylamide; LHRH: luteinizing-hormone release hormone.
|
